Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Hair regrowth after 13 weeks using topical minoxidil, oral finasteride, peptide shampoo, serum, and a red light hat. Some growth is attributed to a recent hair transplant.

A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.

A 27-year-old shared a 90-day hair loss treatment update using Dutasteride, Minoxidil, Tretinoin, Ketoconazole, and microneedling, reporting positive results with improved hairline and density. They experienced minor side effects and noted a decrease in hair shedding.

Hair fibers impressively cover bald spots, boosting confidence. User started big 3 treatment (0.5mg fin, 1 time minoxidil 5% topical, ketoconazole 2%) for regrowth.

Regrowth from using a regimen of finasteride and topical minoxidil daily, with additional microneedling since January 2023, as well as intermittent usage of nizoral and biotin tablets. The replies suggest that the user has seen positive results in their hairline.

A user's hair loss treatment regimen, which includes minoxidil, ketoconazole shampoo and microneedling; some participants questioned the results due to previous posts about hair transplants, but others agreed that quick results are possible with certain treatments.

Microneedling at 0.5mm is more effective than at 1mm and 1.5mm for hair loss. Users discuss switching to 0.5mm and combining it with Minoxidil.

A 25-year-old male experienced hair regrowth after 4.5 months using a chewable treatment with 1mg finasteride, 6% minoxidil, and 2.5mg biotin, despite initial shedding and acne from accutane. Opinions on progress vary, with some noticing thicker hair and others seeing no difference or thinning.

A 17-year-old is addressing hair loss with finasteride, topical minoxidil, and microneedling. They are considering adding GHK-Cu to their regimen, but others advise caution with finasteride due to age.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

The user is experiencing hair regrowth with oral minoxidil and dutasteride but still has fragile hairs that easily pluck out from the front center. Despite improvements, the user is concerned about the persistent fragility and shedding of these hairs.

User tried Min/Fin/Dut and Topical Biotin for hair loss. Some say it's not working, while others appreciate the progress.

A user improved their hair loss from NW3+ to NW1.5 over three years using a regimen of dutasteride, finasteride, Nizoral, biotin, and collagen. They experienced some side effects and adjusted dosages over time, and noted additional benefits like better skin and muscle gain.

GHK-Cu peptide injections are discussed for hair growth, but users report mixed results and suggest focusing on DHT management first. Some users combine GHK-Cu with treatments like Minoxidil and Dutasteride, but emphasize its benefits for skin rather than hair.

A 29-year-old man experienced significant hair thickening at the front and top after using finasteride and microneedling for two months, as noticed by his hairdresser. He used 0.5 mg/day of finasteride orally, switched to a topical solution, and performed microneedling with a Derminator2 every 6-7 days.

A user shared their 10-month progress using Finasteride, Minoxidil, and a Derma Roller for hair loss, showing significant improvement in hair coverage and hairline. Some commenters questioned the before and after photos, while others congratulated the user on the successful results.

A user shared their 7-month progress on hair regrowth using a regimen of dutasteride, minoxidil, stemoxydine, microneedling, and keto shampoo. They noted significant improvement, particularly in vellus hair growth, and discussed the potential addition of RU58841, though they experienced side effects with it previously.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

User is using a homemade topical treatment with .015% finasteride, 5% minoxidil, and microneedling at .75mm depth. They also use 2% ketoconazole shampoo, various oils, and are considering increasing finasteride concentration due to mixed results.

BPC-157 may promote hair growth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.